文献速递糖尿病

Teplizumab在8岁以下2期1型糖尿病儿童中的安全性与药代动力学

Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.
PubMed 文献 · Diabetologia · 2025-11-06

PETITE-T1D是一项单臂、开放标签、多中心研究,纳入23例8岁以下2期1型糖尿病儿童,接受14天Teplizumab疗程。预设中期分析显示,所有参与者出现至少1起TEAE,多为轻中度,无4级或5级TEAE;3例(13%)因TEAE停药,2例(9%)发生SAE,2例进展至3期1型糖尿病。结论认为Teplizumab在该人群中安全且耐受良好,不良事件与既往研究一致,未发现新的安全风险。

要点

  • 8岁以下2期1型糖尿病儿童接受14天Teplizumab疗程,不良事件多为轻中度,无4级或5级TEAE。
  • 3例(13%)因贫血、肝酶升高或斑丘疹导致停药,2例(9%)各发生2起SAE。
  • 中期分析时无进展至3期1型糖尿病的估计概率为89.6%(95% CI 64.3%, 97.3%)。

核心结论

  • Teplizumab在8岁以下2期1型糖尿病儿童中安全且耐受良好,不良事件与既往研究一致,未发现新的安全风险。
  • 观察期内2例参与者进展至3期1型糖尿病,监测仍在进行中。

研究设计与样本

  • PETITE-T1D试验为2年单臂、开放标签、多中心研究,纳入23例8岁以下2期1型糖尿病儿童。
  • 参与者接受14天Teplizumab疗程;在15例完成1年随访后进行预设中期分析,纳入全部23例参与者。
  • 主要终点包括治疗中出现的不良事件(TEAE)、导致治疗停药的TEAE和严重不良事件(SAE)。

主要发现

  • 参与者平均年龄4.8岁(范围1.7-6.8),中位随访时间51.9周(范围3.9-77.1)。
  • 所有参与者均发生至少1起TEAE,大多数为轻中度;未报告4级或5级TEAE。
  • 3例参与者(13%)发生导致Teplizumab停药的TEAE:贫血、肝酶升高和斑丘疹。
  • 2例参与者(9%)各发生2起SAE。
  • 血清Teplizumab浓度在第14天达峰;2例参与者进展至3期1型糖尿病,中期分析时无进展至3期的估计概率为89.6%(95% CI 64.3%, 97.3%)。

关键数值与推荐

  • Teplizumab在美国及另外七个国家获批用于延迟8岁及以上2期1型糖尿病个体进展至3期1型糖尿病。
  • 本研究为美国食品药品监督管理局上市后要求的一部分,评估8岁以下2期1型糖尿病儿童的安全性和药代动力学。

临床怎么用

  • 对于8岁以下2期1型糖尿病儿童,Teplizumab 14天疗程显示安全性特征与既往研究一致,可作为该年龄段超说明书使用的参考依据。
  • 治疗期间需监测贫血、肝酶升高和皮疹等不良事件,少数患者可能因此停药。

局限性

  • 单臂、开放标签设计,无对照组。
  • 样本量较小(23例),随访时间有限,中期分析时部分参与者随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Teplizumab is approved in the USA and seven other countries to delay stage 3 type 1 diabetes onset in individuals ≥8 years of age with stage 2 type 1 diabetes. As part of a US Food and Drug Administration post-marketing requirement, this study evaluated the safety, tolerability and pharmacokinetics of teplizumab in children aged <8 years with stage 2 type 1 diabetes. METHODS: The PETITE-T1D trial is a 2 year single-arm, open-label, multicentre study of 23 children <8 years of age with stage 2 type 1 diabetes. Participants received a 14 day teplizumab course. A prespecified interim analysis was performed after 15 participants completed 1 year of follow-up and included all 23 participants. Primary endpoints included treatment-emergent adverse events (TEAEs), TEAEs causing treatment discontinuation, and serious adverse events (SAEs). Other endpoints assessed immunogenicity, pharmacokinetics, pharmacodynamics and time from study treatment to stage 3 type 1 diabetes. RESULTS: Mean participant age was 4.8 years (range 1.7-6.8). Median follow-up duration was 51.9 weeks (range 3.9-77.1). All participants experienced one or more TEAE, with most being mild to moderate. No grade 4 or 5 TEAEs were reported. Three participants (13%) had TEAEs leading to teplizumab discontinuation: anaemia, elevated liver enzymes and maculo-papular rash. Two participants (9%) each had two SAEs. Serum teplizumab concentrations peaked at day 14. Two participants progressed to stage 3 type 1 diabetes. The estimated probability of lack of progression to stage 3 was 89.6% (95% CI 64.3%, 97.3%) at the time of interim analysis. CONCLUSIONS/INTERPRETATION: Teplizumab was safe and well tolerated in children <8 years of age with stage 2 type 1 diabetes. Adverse events were consistent with those seen in previous studies, with no new safety risks identified. Two participants progressed to stage 3 type 1 diabetes during the observation period; surveillance is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov NCT05757713.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gitelman SE, Simmons K, Sherr JL, et al. Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes. Diabetologia. 2025. PMID: 41196293. doi:10.1007/s00125-025-06586-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。